Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 3 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Increased risk of nonrelapse mortality post T-cell-replete haploidentical stem cell transplantation in patients with recurrence of acute graft-versus-host disease.
Hematol Oncol. 2022 Oct;40(4):743-751. doi: 10.1002/hon.2999. Epub 2022 Apr 17.
Hematol Oncol. 2022.
PMID: 35385135
While most studies focus on classic or late aGVHD, some patients with previous aGVHD achieve complete remission and later develop another episode of aGVHD. Data on recurrence of aGVHD (RaGVHD) are lacking. This study aimed to identify the incidence, risk factors, and impac …
While most studies focus on classic or late aGVHD, some patients with previous aGVHD achieve complete remission and later develop another ep …
[Effect of ruxolitinib combined with glucocorticoid on cytomegalovirus activation in acute graft-versus-host disease].
Xing SY, Qian K, Zhao YX, Peng B, Yang JJ, Dou LP, Liu DH.
Xing SY, et al.
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):732-737. doi: 10.3760/cma.j.issn.0253-2727.2022.09.004.
Zhonghua Xue Ye Xue Za Zhi. 2022.
PMID: 36709166
Free PMC article.
Chinese.
Objective: To observe the effect of ruxolitinib combined with glucocorticoid on cytomegalovirus (CMV) activation in patients with acute graft-versus-host disease (aGVHD) . Methods: The clinical data of 195 patients who underwent allogeneic hematopoietic stem cell transplan …
Objective: To observe the effect of ruxolitinib combined with glucocorticoid on cytomegalovirus (CMV) activation in patients with acute graf …
Item in Clipboard
Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy.
Yang J, Peng B, Wang L, Li X, Li F, Jin X, Jia M, Xu L, Dou L, Liu D.
Yang J, et al.
Ann Hematol. 2022 Mar;101(3):621-630. doi: 10.1007/s00277-021-04727-1. Epub 2021 Nov 23.
Ann Hematol. 2022.
PMID: 34816294
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite